---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-126400"
form_type: "8-K"
ticker: "ELOX"
cik: "0001035354"
company_name: "Eloxx Pharmaceuticals, Inc."
filed_at: "2023-12-15T23:59:59+00:00"
generated_at: "2026-06-07T11:37:13.842492+00:00"
event_type: "debt"
sentiment: "negative"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Eloxx amends Hercules loan, repays $1M; cash covenant lowered to $1.05M through Jan 2024

## Summary
- Minimum qualified cash reduced to $1.05M from Dec 15, 2023 to Jan 25, 2024.
- Company repaid $1.0M of principal; remaining Term Loan principal is $3.1M.
- After Jan 25, minimum cash reverts to $1.05M plus accounts payable unpaid over 180 days.
- Amendment provides temporary liquidity relief amid cash constraints.

## SEC filing metadata
- accession: 0001104659-23-126400
- form_type: 8-K
- ticker: ELOX
- cik: 0001035354
- company_name: Eloxx Pharmaceuticals, Inc.
- filed_at: 2023-12-15T23:59:59+00:00
- event_type: debt
- sentiment: negative
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 1.01, 2.03
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1035354/000110465923126400/0001104659-23-126400-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1035354/000110465923126400/tm2332971d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-126400
- JSON: https://secwatch.observer/filing/0001104659-23-126400.json
- Plain text: https://secwatch.observer/filing/0001104659-23-126400.txt

## Key facts
- Debt Financings
  Eloxx Pharmaceuticals, Inc. amended credit facility of reducing the remaining outstanding principal of Term Loan Advances to $3.1 million with Hercules Capital, Inc., Hercules Capital IV, L.P..
  - Instrument: credit facility
  - Principal: reducing the remaining outstanding principal of Term Loan Advances to $3.1 million
  - Counterparty: Hercules Capital, Inc., Hercules Capital IV, L.P.
  - Event: amendment
  source text: the Company has repaid $1.0 million of the outstanding principal (without incurring a prepayment premium), reducing the remaining outstanding principal of Term Loan Advances to $3.1 million. The foregoing description of the Fourth Amendment does not purport to be complete and is qualified in its entirety by reference to the full text of the Fourth Amendment, a copy
  evidence_url: https://www.sec.gov/Archives/edgar/data/1035354/000110465923126400/0001104659-23-126400-index.htm
- Material Agreements
  Eloxx Pharmaceuticals, Inc. amended Fourth Amendment with Hercules Capital, Inc. valued at $1.0 million (effective 2023-12-15).
  - Action: amendment
  - Agreement: credit facility
  - Counterparty: Hercules Capital, Inc.
  - Value: $1.0 million
  - Effective: 2023-12-15
  source text: On December 15, 2023, Eloxx Pharmaceuticals, Inc. (the “Company”) entered into the Fourth Amendment to the Loan and Security Agreement
  evidence_url: https://www.sec.gov/Archives/edgar/data/1035354/000110465923126400/0001104659-23-126400-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.